

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date: Wednesday, May 20, 2026
Time: 3:00 pm Eastern Time
Location: Zoom Teleconference
Institution: McGill University Health Centre, Montreal, Quebec
Principal Investigator: Mark Sherman, MD, CM, FRCPC, FNLA
Protocol: Verve Therapeutics, Inc., VT-10201
NCT Number: NCT06164730
Meeting Type: Initial Review of Protocol and Site
Title: Open-label, Phase 1b, single ascending dose study to evaluate the safety of VERVE-102 administered to patients with heterozygous familial hypercholesterolemia or premature coronary artery disease who require additional lowering of lowdensity lipoprotein cholesterol

1. Call to order:

The Meeting was called to order at 3:01 pm Eastern Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Four voting members were present, including two local members unaffiliated with the institution. Also present were the Institutional Biosafety Officer and IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

The Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

6. Review of proposed research:

The Chair provided an overview of the protocol.

The Chair provided an overview of the biosafety risk assessment for the protocol.

7. Determination for biosafety level and period of IBC oversight:

The Committee determined that **BSL-2 containment facilities and practices** are required for VERVE-102 since it consists of mRNA and CRISPR RNA that can modify the cellular genome.

The Committee determined that IBC oversight will continue for **3 months after the last subject's last dose of VERVE-102 locally**, provided that other biosafety criteria for study closure are also met.

8. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 3

NO: 0

ABSTAIN: 0

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

9. Review of Principal Investigator qualifications:

The Committee reviewed and accepted the qualifications of the Principal Investigator.

10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

Point of Discussion:

1. The Biosafety Officer could not confirm how many subjects will be enrolled at the site.

11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval with the Biosafety Officer.

12. Vote on the Site:

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 4

NO: 0

ABSTAIN: 0

13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 3:09 pm Eastern Time.

15. Post-meeting notes: None.

Documents reviewed:

Agenda

Global Protocol, Amendment 3.0, Version 4.0, dated 09-03-2025

Investigator's Brochure, Version 3.0, dated 09-09-2025

Pharmacy Manual, Version 6.0, dated 02-24-2026

Biological Risk Assessment and Summary, dated 05-13-2026

Site Map, 4th floor C04.35, dated 03-16-2026

Site Map, Central Pharmacy, dated 05-05-2026

Site Map, Onc. Pharm., Clean Rm, D01.6335.2, dated 04-29-2026

Site Map, Biohazardous Waste Storage, dated 03-16-2026

Site Inspection Checklist, McGill University Health Centre, expires 08-13-2026, updated 05-04-2026

Photos, 4th floor C04.35 and Waste, dated 05-05-2026

Photos, Central Pharmacy Inv., C01.6010.3, dated 05-03-2026

Photos, Onc. Pharm, Clean Rm, D01.6335.1 & 2, dated 05-01-2026

Biohazard Sign, BSL2, Dosing Area, dated 05-19-2026

Biohazard Sign, BSL2, Oncology Pharmacy Clean Room, dated 05-19-2026

Biological Safety Cabinet Certifications, dated 02-26-2026

SOP, Biosafety for VERVE-102, dated 05-20-2026

Training, Shipping Certifications, expire 08-12-2027, 12-05-2027

CV, Sherman, M., signed 04-22-2026